---
title: "Enliven Therapeutics, Inc. (ELVN.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ELVN.US.md"
symbol: "ELVN.US"
name: "Enliven Therapeutics, Inc."
industry: "Pharmaceuticals"
datetime: "2026-05-20T12:04:46.304Z"
locales:
  - [en](https://longbridge.com/en/quote/ELVN.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ELVN.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ELVN.US.md)
---

# Enliven Therapeutics, Inc. (ELVN.US)

## Company Overview

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.enliventherapeutics.com](https://www.enliventherapeutics.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -24.77 | 211 | - | - | - |
| PB | 5.40 | 153 | 4.41 | 3.29 | 2.43 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-12T04:00:00.000Z

Total Analysts: **9**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 9 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 40.17 |
| Highest Target | 80.00 |
| Lowest Target | 45.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/ELVN.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/ELVN.US/norm.md)
- [Related News](https://longbridge.com/en/quote/ELVN.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/ELVN.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**